vs
Side-by-side financial comparison of TECHPRECISION CORP (TPCS) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $7.1M, roughly 1.9× TECHPRECISION CORP). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -20.8%, a 96.5% gap on every dollar of revenue. TECHPRECISION CORP produced more free cash flow last quarter ($-827.0K vs $-2.1M).
TechPrecision Corp is a manufacturer of custom high-precision metal fabricated components and integrated systems, serving aerospace, defense, medical technology, renewable energy, and industrial end markets primarily across North America and Europe. It specializes in producing tight-tolerance, mission-critical parts that adhere to rigorous industry quality requirements.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
TPCS vs XLO — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $13.7M |
| Net Profit | $-1.5M | $10.4M |
| Gross Margin | 5.4% | — |
| Operating Margin | -19.1% | -86.5% |
| Net Margin | -20.8% | 75.7% |
| Revenue YoY | -6.9% | — |
| Net Profit YoY | -84.4% | 179.1% |
| EPS (diluted) | $-0.15 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.1M | $13.7M | ||
| Q3 25 | $9.1M | $19.1M | ||
| Q2 25 | $7.4M | $8.1M | ||
| Q1 25 | $9.5M | $2.9M | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | $8.6M | — |
| Q4 25 | $-1.5M | $10.4M | ||
| Q3 25 | $825.0K | $-16.3M | ||
| Q2 25 | $-597.0K | $-15.8M | ||
| Q1 25 | $112.0K | $-13.3M | ||
| Q4 24 | $-799.0K | — | ||
| Q3 24 | $-601.0K | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-5.1M | — |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 14.0% | — | ||
| Q1 25 | 22.0% | — | ||
| Q4 24 | 13.0% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 14.3% | — |
| Q4 25 | -19.1% | -86.5% | ||
| Q3 25 | 10.4% | -10.1% | ||
| Q2 25 | -6.3% | -177.7% | ||
| Q1 25 | 3.9% | -472.7% | ||
| Q4 24 | -9.1% | — | ||
| Q3 24 | -5.5% | — | ||
| Q2 24 | -16.8% | — | ||
| Q1 24 | -28.6% | — |
| Q4 25 | -20.8% | 75.7% | ||
| Q3 25 | 9.1% | -85.4% | ||
| Q2 25 | -8.1% | -196.0% | ||
| Q1 25 | 1.2% | -452.7% | ||
| Q4 24 | -10.5% | — | ||
| Q3 24 | -6.7% | — | ||
| Q2 24 | -18.3% | — | ||
| Q1 24 | -59.5% | — |
| Q4 25 | $-0.15 | $-3.74 | ||
| Q3 25 | $0.08 | $-0.11 | ||
| Q2 25 | $-0.06 | $-0.16 | ||
| Q1 25 | $0.01 | $-0.18 | ||
| Q4 24 | $-0.08 | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $-0.16 | — | ||
| Q1 24 | $-0.59 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.0K | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.0M | $35.3M |
| Total Assets | $32.8M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.0K | $137.5M | ||
| Q3 25 | $220.0K | $103.8M | ||
| Q2 25 | $143.0K | $121.6M | ||
| Q1 25 | $195.0K | $89.1M | ||
| Q4 24 | $165.0K | — | ||
| Q3 24 | $132.0K | — | ||
| Q2 24 | $44.8K | — | ||
| Q1 24 | $138.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $3.0K | — | ||
| Q4 24 | $19.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $8.0M | $35.3M | ||
| Q3 25 | $9.1M | $-8.1M | ||
| Q2 25 | $8.2M | $7.1M | ||
| Q1 25 | $8.7M | $10.7M | ||
| Q4 24 | $8.1M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $7.9M | — | ||
| Q1 24 | $7.8M | — |
| Q4 25 | $32.8M | $154.7M | ||
| Q3 25 | $33.8M | $133.7M | ||
| Q2 25 | $32.1M | $133.8M | ||
| Q1 25 | $33.5M | $103.7M | ||
| Q4 24 | $32.2M | — | ||
| Q3 24 | $35.0M | — | ||
| Q2 24 | $35.7M | — | ||
| Q1 24 | $34.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.0K | $-2.0M |
| Free Cash FlowOCF − Capex | $-827.0K | $-2.1M |
| FCF MarginFCF / Revenue | -11.7% | -15.3% |
| Capex IntensityCapex / Revenue | 14.2% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.0K | $-2.0M | ||
| Q3 25 | $-1.1M | $-17.5M | ||
| Q2 25 | $646.0K | $-14.5M | ||
| Q1 25 | $396.0K | $29.0M | ||
| Q4 24 | $-570.0K | — | ||
| Q3 24 | $-532.0K | — | ||
| Q2 24 | $107.0K | — | ||
| Q1 24 | $-452.0K | — |
| Q4 25 | $-827.0K | $-2.1M | ||
| Q3 25 | $-2.1M | — | ||
| Q2 25 | $-604.0K | $-14.9M | ||
| Q1 25 | $-930.0K | $29.0M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-2.0M | — | ||
| Q2 24 | $-94.0K | — | ||
| Q1 24 | $-900.0K | — |
| Q4 25 | -11.7% | -15.3% | ||
| Q3 25 | -22.9% | — | ||
| Q2 25 | -8.2% | -184.0% | ||
| Q1 25 | -9.8% | 988.3% | ||
| Q4 24 | -22.9% | — | ||
| Q3 24 | -21.8% | — | ||
| Q2 24 | -1.2% | — | ||
| Q1 24 | -10.5% | — |
| Q4 25 | 14.2% | 0.7% | ||
| Q3 25 | 11.0% | 0.0% | ||
| Q2 25 | 16.9% | 5.0% | ||
| Q1 25 | 14.0% | 0.8% | ||
| Q4 24 | 15.4% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 5.2% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | -1.31× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.54× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TPCS
| Defense | $6.7M | 94% |
| Other | $410.0K | 6% |
XLO
Segment breakdown not available.
